Research
Hormonal
Dual GIP/GLP-1 receptor agonists (e.g., tirzepatide) produce greater weight loss than GLP-1RAs alone (e.g., semaglutide) in both diabetic and non-diabetic populations, while potentially reducing nausea through GIP receptor signaling.
Tirzepatide (5-15 mg weekly) is more effective for weight loss than semaglutide in patients with type 2 diabetes, achieving 8.5-12.4% weight loss compared to 6.7% for semaglutide. It works by targeting both GIP and GLP-1 receptors, potentially offering a better side effect profile regarding nausea.
StrongSupportsVERY_HIGH confidence
Tirzepatide has demonstrated significant weight loss effects in phase III clinical trials... Furthermore, tirzepatide has shown greater weight loss effects than the GLP-1RA semaglutide. In a clinical trial of patients with type 2 diabetes, weekly tirzepatide at 5, 10, or 15 mg for 40 weeks resulted in an 8.5–12.4% weight loss, compared to 6.7% with semaglutide at 1 mg/week [29].
Why this rating
Supported by multiple Phase III trials (SURPASS, SURMOUNT) with robust data.
Source
Comparing the anorexigenic effects and mechanisms of gut-derived GLP-1 and its receptor agonists: insights into incretin-based therapies for obesity
Yuta Masuda et al. · Diabetology International · 2025
narrative_reviewCited 10×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →